Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse

Table 1 Correlation between M2e-specific serum Ab titer and reduction of virus titer in various sites of the respiratory tract after parenteral and i.n. immunization.

Specificity/Isotype of anti-M2e Abs	Spearman correlation coefficient r (p)
	parenteral vaccination			i.n. vaccination
	Nose	Trachea	Lung	Nose	Trachea	Lung
M2e(pep)	0.07	-0.03	0.18	0.2	0.24	0.02
M2e(pep-nat)	0.96(***)	0.82 (**)	0.8 (**)	-0.38	-0.27	-0.31
M2e(pep-nat) G2a	0.56	0.51	0.75 (*)	-0.43	-0.30	-0.35

Mean (4–5 mice/group) M2e-specific serum Ab titers 7–10 days before challenge with X31 virus (5 μl, 10³ TCID₅₀) were analyzed for correlation with mean reduction (compared to control group) of virus titers in nose, trachea and lung. Included in the analysis are 9 groups of mice immunized with M2e-MAP by a parenteral route (s.c., i.m., i.p.) and 14 groups immunized by the i.n. route. Statistical significance of correlation (Spearman r, non parametric) is indicated by asterisk: (*): p < 0.05, (**): p = 0.01, (***): p = 0.002.

ISSN: 1743-422X